HBsAg, Anti-Hepatitis C Virus and Anti-HIV Seroprevalence Among Patients Admitted to Our Hospital between 2005 and 2013

Abstract

OZET Objectives: Hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV infections constitute a major health problem in our country as is in the world. This study intended to determine the distribution of the seropositivity rates for HBsAg, antiHCV, and anti-HIV according to genders, age groups, and years in patients admitted to our hospital. Materials and Methods: We retrospectively analyzed HBsAg, anti-HCV, and anti-HIV test results in patients admitted to our hospital between June 2005 and December 2013. The tests were conducted using the methods of chemiluminescent microparticle immunoassay (Architect i 1000, Abbott, USA), chemiluminescent immunoassay (Vitros ECI Q, Ortho Clinical Diagnostics, USA, ADVIA Centaur BayerSiemens, Germany), and electro-chemiluminescence immunoassay (Cobas 6000, Roche Diagnostic GmbH, Germany). Results: The seropositivity rates and the number of the samples studied were as follows: HBsAg was found in 3.379 out of 152608 patients (2.21%), anti-HCV in 877 out of 155.585 patients (0.56%) and anti-HIV in one out of 125.084 patients (0.0008%). Positivity rate distribution by gender was determined as 39.42% of females and 60.58% of males for HBsAg; 53.48% of females and 46.52% of males for anti-HCV. The only sample found to be positive in anti-HIV test belongs to a female patient. Conclusion: Our HBsAg positivity rate was relatively low whereas anti-HIV and anti-HCV results were found to be similar with the country statistical data. (Viral Hepatitis Journal 2014; 20(3): 125-130)